Medications for Precursor Cell Lymphoblastic Leukemialymphoma

33 results

  • Cyclophosphamide (cyclophosphamide for injection)

    (Cyclophosphamide for Injection)
    Slate Run Pharmaceuticals, LLC
    Usage: Cyclophosphamide for Injection is indicated for treating various malignancies, including malignant lymphomas, multiple myeloma, leukemias, and solid tumors like breast cancer and ovarian adenocarcinoma. It is also used for pediatric patients with biopsy-proven minimal change nephrotic syndrome unresponsive to corticosteroid therapy.

  • Cyclophosphamide (cyclophosphamide)

    (cyclophosphamide)
    Dr. Reddy's Laboratories Inc.
    Usage: Cyclophosphamide is indicated for treating malignant diseases in adults and pediatric patients, including various lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, and breast carcinoma. It is often used in combination with other antineoplastic agents.

  • Cyclophosphamide (cyclophosphamide)

    (cyclophosphamide)
    Civica, Inc.
    Usage: Cyclophosphamide for Injection is indicated for treating various malignant diseases in adults and children, including malignant lymphomas, multiple myeloma, leukemias, and neuroblastoma. It is also used for pediatric patients with minimal change nephrotic syndrome who do not respond to or cannot tolerate corticosteroids.

  • Cyclophosphamide (cyclophosphamide)

    (cyclophosphamide)
    Bamboo US BidCo LLC
    Usage: Cyclophosphamide is indicated for treating various malignant diseases, including advanced lymphomas, multiple myeloma, leukemias, and certain solid tumors. It is also used for pediatric patients with biopsy-proven minimal change nephrotic syndrome who have not responded to corticosteroid therapy. Safety in adults for nephrotic syndrome is unestablished.

  • Cyclophosphamide (cyclophosphamide)

    (cyclophosphamide)
    NextSource Pharma
    Usage: Cyclophosphamide Capsules are indicated for treating various malignant diseases, including malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric minimal change nephrotic syndrome unresponsive to corticosteroids.

  • Cytarabine (cytarabine)

    (Cytarabine)
    Meitheal Pharmaceuticals Inc.
    Usage: Cytarabine Injection, in combination with other anti-cancer drugs, is indicated for remission induction in acute non-lymphocytic leukemia, acute lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia. It is also used intrathecally for prophylaxis and treatment of meningeal leukemia.

  • Dasatinib (dasatinib)

    (Dasatinib)
    Dr. Reddy's Laboratories Inc.
    Usage: Dasatinib tablets are indicated for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and those with advanced Ph+ CML or Ph+ acute lymphoblastic leukemia (ALL) who are resistant or intolerant to prior therapy. They are also approved for pediatric patients with Ph+ CML and newly diagnosed Ph+ ALL.

  • Dasatinib (dasatinib)

    (dasatinib)
    Biocon Pharma Inc.
    Usage: Dasatinib is indicated for treating adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase, Ph+ CML with resistance to prior therapy, and Ph+ acute lymphoblastic leukemia (ALL). It is also indicated for pediatric patients aged 1 and older with Ph+ CML and newly diagnosed Ph+ ALL.

  • Dasatinib (dasatinib)

    (Dasatinib)
    Apotex Corp.
    Usage: Dasatinib tablets are indicated for adults with newly diagnosed Ph+ chronic myeloid leukemia (CML) in chronic phase, resistant or intolerant Ph+ CML, and Ph+ acute lymphoblastic leukemia (ALL). It is also for pediatric patients (1 year and older) with Ph+ CML and newly diagnosed Ph+ ALL with chemotherapy.

  • Dasatinib (dasatinib)

    (dasatinib)
    Prasco Laboratories
    Usage: Dasatinib tablets are indicated for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML), Ph+ CML with resistance/intolerance to prior therapy, and Ph+ acute lymphoblastic leukemia (ALL). They are also indicated for pediatric patients (≥1 year) with Ph+ CML and newly diagnosed Ph+ ALL with chemotherapy.